Khan Fauzia A, Ullah Hameed
Department of Anaesthesiology, Aga Khan University Hospital, Karachi, Pakistan.
Cochrane Database Syst Rev. 2013 Jul 3;2013(7):CD004087. doi: 10.1002/14651858.CD004087.pub2.
Several drugs have been used in attenuating or obliterating the response associated with laryngoscopy and tracheal intubation. These changes are of little concern in relatively healthy patients but can lead to morbidity and mortality in the high risk patient population.
The primary objective of this review was to determine the effectiveness of pharmacological agents in preventing the morbidity and mortality resulting from the haemodynamic changes in response to laryngoscopy and tracheal intubation in adult patients aged 18 years and above who were undergoing elective surgery in the operating room setting.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 6), MEDLINE (1950 to June 2011), EMBASE (1980 to June 2011), and the bibliographies of published studies. We reran our search from June 2011 to December 2012 and will deal with these studies when we update the review.
We included randomized controlled trials (RCTs) that compared a drug used as an intervention for preventing or attenuating the haemodynamic response to tracheal intubation to a control group, and that mentioned mortality, major morbidity, arrhythmia or electrocardiogram (ECG) evidence of ischaemia in the methodology, results, or discussion section of the reports.
Two authors independently assessed trial quality and extracted the outcome data.
We included 72 RCTs. The included trials studied the effects of 32 drugs belonging to different pharmacological groups. Only two trials mentioned the primary outcome of morbidity and mortality related to the haemodynamic response to tracheal intubation. Of the secondary outcomes, 40 of the included trials observed arrhythmia only, 11 observed myocardial ischaemia only and 20 observed both arrhythmias and myocardial ischaemia. Arrhythmias were observed in 2932 participants and myocardial ischaemia in 1616 participants. Arrhythmias were observed in 134 out of 993 patients in the control group compared to 80 out of 1939 in the intervention group. The risk of arrhythmias was significantly reduced with pharmacological interventions in the pooled data (Peto odds ratio (OR) 0.19, 95% CI 0.14 to 0.26, P < 0.00001, I(2)= 47%). Local anaesthetics, calcium channel blockers, beta blockers and narcotics reduced the risk of arrhythmia in the intervention group compared to the control group. Myocardial ischaemia was observed in 21 out of 604 patients in the control group compared to 10 out of 1012 in the treatment group; the result was statistically significant (Peto OR 0.45, 95% CI 0.22 to 0.92, P = 0.03, I(2) = 19%). However, in subgroup analysis only local anaesthetics significantly reduced the ECG changes indicating ischaemia, but this evidence came from one study. The majority of the studies had a negative outcome. Hypotension and bradycardia were reported with 40 µg kg(-1) intravenous alfentanil, chest rigidity with 75 ug kg(-1) alfentanil, and increased bronchomotor tone with sympathetic blockers.There were 17 studies which included high risk patients. Pharmacological treatment in this group resulted in the reduction of arrhythmias when the data from nine trials looking at arrhythmias were pooled (Peto OR 0.18, 95% CI 0.05 to 0.59, P = 0.005, I(2) = 80%). The analysis from four studies was not included. Three of these trials looked at the effect of sympathetic blockers but arrhythmias or myocardial ischaemia was observed throughout the perioperative period in two studies and some patients had arrhythmias due to atropine premedication in the third study. In the fourth study the authors mentioned myocardial ischaemia in the objectives section but did not report it in the results.
AUTHORS' CONCLUSIONS: The risk of arrhythmias associated with tracheal intubation was significantly reduced with pre-induction administration of local anaesthetics, calcium channel blockers, beta blockers and narcotics compared to placebo. Pharmacological intervention also reduced the risk of ECG evidence of myocardial ischaemia in the pooled data. Lignocaine pretreatment showed a significant effect but evidence came from one study only. The data suggested that there may be a reduction in ECG evidence of myocardial ischaemia with beta blocker pretreatment but this difference was not statistically significant. There is a need to focus on outcomes rather than haemodynamic measurements alone when studying this response in future trials.
已有多种药物用于减轻或消除与喉镜检查和气管插管相关的反应。这些变化在相对健康的患者中不太受关注,但在高危患者群体中可能导致发病和死亡。
本综述的主要目的是确定药物制剂在预防18岁及以上成年患者在手术室进行择期手术时,因喉镜检查和气管插管引起的血流动力学变化导致的发病和死亡方面的有效性。
我们检索了Cochrane对照试验中央注册库(CENTRAL)(2011年第6期)、MEDLINE(1950年至2011年6月)、EMBASE(1980年至2011年6月)以及已发表研究的参考文献。我们重新进行了从2011年6月至2012年12月的检索,并将在更新综述时处理这些研究。
我们纳入了随机对照试验(RCT),这些试验将用作预防或减轻气管插管血流动力学反应的干预药物与对照组进行比较,并且在报告的方法、结果或讨论部分提及了死亡率、主要发病率、心律失常或缺血的心电图(ECG)证据。
两位作者独立评估试验质量并提取结果数据。
我们纳入了72项RCT。纳入的试验研究了属于不同药理学组的32种药物的效果。只有两项试验提到了与气管插管血流动力学反应相关的发病和死亡的主要结局。在次要结局中,纳入的试验中有40项仅观察到心律失常,11项仅观察到心肌缺血,20项同时观察到心律失常和心肌缺血。2932名参与者出现心律失常,1616名参与者出现心肌缺血。对照组993名患者中有134名出现心律失常,干预组1939名患者中有80名出现心律失常。汇总数据显示,药物干预显著降低了心律失常的风险(Peto比值比(OR)0.19,95%可信区间0.14至0.26,P<0.00001,I² = 47%)。与对照组相比,局部麻醉药、钙通道阻滞剂、β受体阻滞剂和麻醉药降低了干预组心律失常的风险。对照组604名患者中有21名出现心肌缺血,治疗组1012名患者中有10名出现心肌缺血;结果具有统计学意义(Peto OR 0.45,95%可信区间0.22至0.92,P = 0.03,I² = 19%)。然而,在亚组分析中,只有局部麻醉药显著降低了提示缺血的ECG变化,但这一证据仅来自一项研究。大多数研究结果为阴性。静脉注射40μg/kg阿芬太尼可导致低血压和心动过缓,75μg/kg阿芬太尼可导致胸壁强直,交感神经阻滞剂可导致支气管运动张力增加。有17项研究纳入了高危患者。当汇总9项观察心律失常的试验数据时,该组的药物治疗导致心律失常减少(Peto OR 0.18,95%可信区间0.05至0.59,P = 0.005,I² = 80%)。未纳入4项研究的分析。其中3项试验研究了交感神经阻滞剂的效果,但两项研究在整个围手术期均观察到心律失常或心肌缺血,第三项研究中一些患者因阿托品预处理出现心律失常。在第四项研究中,作者在目标部分提到了心肌缺血,但结果中未报告。
与安慰剂相比,诱导前给予局部麻醉药、钙通道阻滞剂、β受体阻滞剂和麻醉药可显著降低气管插管相关心律失常的风险。药物干预在汇总数据中也降低了ECG提示心肌缺血的风险。利多卡因预处理显示出显著效果,但证据仅来自一项研究。数据表明,β受体阻滞剂预处理可能会使ECG提示心肌缺血的情况减少,但这种差异无统计学意义。在未来的试验中,研究这种反应时需要关注结局而非仅关注血流动力学测量。